Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease
Launched by LONDON HEALTH SCIENCES CENTRE RESEARCH INSTITUTE OR LAWSON RESEARCH INSTITUTE OF ST. JOSEPH'S · Jul 23, 2007
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with an eGFR between 30-60 ml/min calculated using last available creatinine and patient weight.
- • 2. Age \> 18
- • 3. No known allergies to or adverse effects from NAC
- • 4. No known scheduled radio-contrast procedures
- • 5. No medications known to affect creatinine secretion
About London Health Sciences Centre Research Institute Or Lawson Research Institute Of St. Joseph's
The London Health Sciences Centre Research Institute, affiliated with Lawson Health Research Institute at St. Joseph's Health Care, is dedicated to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into practical applications, the institute fosters collaboration among leading researchers, clinicians, and healthcare professionals. It aims to improve patient outcomes and enhance the quality of care through rigorous investigation in areas such as cancer, cardiovascular health, and neuroscience. By integrating cutting-edge research with clinical practice, the institute plays a pivotal role in shaping the future of healthcare delivery in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
Patients applied
Trial Officials
Louise Moist, MD, MSC
Principal Investigator
Schulich School of Medicine and Dentistry, University of Western Ontario
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials